Elizabeth Nabel - Tekla Healthcare Independent Trustee
| HQH Stock | USD 17.18 0.54 3.05% |
Executive
Dr. Elizabeth G. Nabel M.D., is the Independent Trustee of the Company. Dr. Nabel is President of Brigham Health, which includes Brigham and Women Hospital, Brigham and Women Faulkner Hospital, and the Brigham and Women Physician Organization. She is also Professor of Medicine at Harvard Medical School. Dr. Nabel also serves as a Director of Medtronic plc and Moderna Therapeutics Inc. Dr. Nabel provides the Fund with valuable insight into biomedical research and academic medicine. She serves on the Audit Committee of each Fund. Her research on the molecular genetics of cardiovascular disease has produced 17 patents and over 250 publications. Dr. Nabel was named as one of the 50 most influential physician executives in the nation by Modern Healthcare in 2016 and as a hospital and health system leader by Becker Hospital Review in 2017. She has received many awards, including the Kober Medal from the Association of American Physicians, the Champion in Health Care award from the Boston Business Journal, the Willem Einthoven Award from Leiden University in the Netherlands, the AmgenScientific Achievement Award, two Distinguished Achievement Awards and the Eugene Braunwald Academic Mentorship Award from the American Heart Association since 2018.
| Age | 67 |
| Tenure | 6 years |
| Professional Marks | Ph.D |
| Address | 1900 Market Street, Philadelphia, PA, United States, 19103 |
| Phone | 215 405 5700 |
| Web | https://www.teklacap.com/hqh.html |
Tekla Healthcare Management Efficiency
The Tekla Healthcare's current Return On Tangible Assets is estimated to increase to 0.08. The Tekla Healthcare's current Return On Capital Employed is estimated to increase to 0.06. As of now, Tekla Healthcare's Asset Turnover is decreasing as compared to previous years. Tekla Healthcare's management efficiency ratios could be used to measure how well Tekla Healthcare manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Richard Cochran | Allianzgi Equity Convertible | 59 | |
| Lisa Phelan | Cohen Steers Closed | 51 | |
| Lisa Phelan | Cohen Steers Qualityome | 52 | |
| James Kirchner | Eaton Vance Tax | 54 | |
| Mark Fetting | Eaton Vance Tax | 67 | |
| James Jacobson | Allianzgi Equity Convertible | 75 | |
| Lisa Curcio | Royce Micro Cap | 60 | |
| Helen Peters | Eaton Vance Tax | 73 | |
| Thomas Faust | Eaton Vance Tax | 63 | |
| William Reardon | Tekla Healthcare Opportunities | 74 | |
| Orhan Dzemaili | Allianzgi Equity Convertible | 46 | |
| Lucinda Stebbins | Tekla World Healthcare | 73 | |
| Albert Laskaj | Cohen And Steers | 43 | |
| Rakesh Jain | Tekla Life Sciences | 69 | |
| Scott Wennerholm | Eaton Vance Tax | 62 | |
| Linda Puchalski | Flaherty and Crumrine | 63 | |
| CFA CFA | Royce Micro Cap | N/A | |
| Susan Sutherland | Eaton Vance Tax | 64 | |
| John Denneen | Royce Micro Cap | 53 | |
| Lisa Phelan | Cohen Steers Reit | 51 | |
| William Reardon | Tekla World Healthcare | 74 | |
Management Performance
| Return On Equity | 0.0734 | ||||
| Return On Asset | -7.0E-4 |
Tekla Healthcare Inv Leadership Team
Elected by the shareholders, the Tekla Healthcare's board of directors comprises two types of representatives: Tekla Healthcare inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tekla. The board's role is to monitor Tekla Healthcare's management team and ensure that shareholders' interests are well served. Tekla Healthcare's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tekla Healthcare's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher MBA, Senior Manager | ||
| Oleg Pohotsky, Independent Chairman of the Board of Trustees | ||
| Dr MS, Portfolio Manager | ||
| Lucinda Stebbins, Independent Trustee | ||
| Jeffrey Bailey, Independent Trustee | ||
| Daniel Omstead, CEO and President Trustee, Member of Valuation Committee, CEO of Hambrecht and Quist Capital Management LLC and President - HQL and President of Hambrecht and Quist Capital Management LLC and Trustee of HQL | ||
| Rakesh Jain, Independent Trustee | ||
| MBA MD, VP Mang | ||
| Frank Gentile, Senior Manager | ||
| Thomas Kent, Independent Trustee | ||
| William Reardon, Independent Trustee | ||
| Elizabeth Nabel, Independent Trustee | ||
| Laura Woodward, Chief Compliance Officer, Treasurer, Secretary |
Tekla Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tekla Healthcare a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0734 | ||||
| Return On Asset | -7.0E-4 | ||||
| Profit Margin | 7.31 % | ||||
| Operating Margin | (0.01) % | ||||
| Current Valuation | 897.06 M | ||||
| Shares Outstanding | 50.62 M | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 26.29 % | ||||
| Number Of Shares Shorted | 74.35 K | ||||
| Price To Earning | 3.38 X |
Currently Active Assets on Macroaxis
When determining whether Tekla Healthcare Inv offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tekla Healthcare's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tekla Healthcare Investors Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tekla Healthcare Investors Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Tekla Healthcare Investors. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Healthcare. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Healthcare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.145 | Dividend Share 1.66 | Earnings Share 1.31 | Revenue Per Share 0.197 | Quarterly Revenue Growth (0.06) |
The market value of Tekla Healthcare Inv is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Healthcare's value that differs from its market value or its book value, called intrinsic value, which is Tekla Healthcare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Healthcare's market value can be influenced by many factors that don't directly affect Tekla Healthcare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tekla Healthcare's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Healthcare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Healthcare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.